Expression of androgen receptors in primary breast cancer

S. Park, J. Koo, H. S. Park, J. H. Kim, S. Y. Choi, J. H. Lee, B. W. Park, K. S. Lee

Research output: Contribution to journalArticle

200 Citations (Scopus)

Abstract

Background: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers. Patients and methods: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008 to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with ≥10% nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-square test. Results: The expression rate of AR was 72.9% higher than those of estrogen receptors (ER) and progesterone receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer. However, AR expression was observed in 35% of triple-negative cancers. Metaplastic, medullary and mucinous types of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human epidermal growth factor receptor type 2 (HER-2) overexpression. Conclusions: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.

Original languageEnglish
Article numbermdp510
Pages (from-to)488-492
Number of pages5
JournalAnnals of Oncology
Volume21
Issue number3
DOIs
Publication statusPublished - 2009 Nov 3

Fingerprint

Androgen Receptors
Breast Neoplasms
Estrogen Receptors
Neoplasms
Triple Negative Breast Neoplasms
Mucinous Adenocarcinoma
Medullary Carcinoma
Progesterone Receptors
Chi-Square Distribution
Tumor Burden
Immunohistochemistry
Hormones
Antigens

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Park, S., Koo, J., Park, H. S., Kim, J. H., Choi, S. Y., Lee, J. H., ... Lee, K. S. (2009). Expression of androgen receptors in primary breast cancer. Annals of Oncology, 21(3), 488-492. [mdp510]. https://doi.org/10.1093/annonc/mdp510
Park, S. ; Koo, J. ; Park, H. S. ; Kim, J. H. ; Choi, S. Y. ; Lee, J. H. ; Park, B. W. ; Lee, K. S. / Expression of androgen receptors in primary breast cancer. In: Annals of Oncology. 2009 ; Vol. 21, No. 3. pp. 488-492.
@article{e94f0366b82b491abf25945d2f7c6b44,
title = "Expression of androgen receptors in primary breast cancer",
abstract = "Background: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers. Patients and methods: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008 to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with ≥10{\%} nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-square test. Results: The expression rate of AR was 72.9{\%} higher than those of estrogen receptors (ER) and progesterone receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer. However, AR expression was observed in 35{\%} of triple-negative cancers. Metaplastic, medullary and mucinous types of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human epidermal growth factor receptor type 2 (HER-2) overexpression. Conclusions: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.",
author = "S. Park and J. Koo and Park, {H. S.} and Kim, {J. H.} and Choi, {S. Y.} and Lee, {J. H.} and Park, {B. W.} and Lee, {K. S.}",
year = "2009",
month = "11",
day = "3",
doi = "10.1093/annonc/mdp510",
language = "English",
volume = "21",
pages = "488--492",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

Park, S, Koo, J, Park, HS, Kim, JH, Choi, SY, Lee, JH, Park, BW & Lee, KS 2009, 'Expression of androgen receptors in primary breast cancer', Annals of Oncology, vol. 21, no. 3, mdp510, pp. 488-492. https://doi.org/10.1093/annonc/mdp510

Expression of androgen receptors in primary breast cancer. / Park, S.; Koo, J.; Park, H. S.; Kim, J. H.; Choi, S. Y.; Lee, J. H.; Park, B. W.; Lee, K. S.

In: Annals of Oncology, Vol. 21, No. 3, mdp510, 03.11.2009, p. 488-492.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of androgen receptors in primary breast cancer

AU - Park, S.

AU - Koo, J.

AU - Park, H. S.

AU - Kim, J. H.

AU - Choi, S. Y.

AU - Lee, J. H.

AU - Park, B. W.

AU - Lee, K. S.

PY - 2009/11/3

Y1 - 2009/11/3

N2 - Background: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers. Patients and methods: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008 to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with ≥10% nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-square test. Results: The expression rate of AR was 72.9% higher than those of estrogen receptors (ER) and progesterone receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer. However, AR expression was observed in 35% of triple-negative cancers. Metaplastic, medullary and mucinous types of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human epidermal growth factor receptor type 2 (HER-2) overexpression. Conclusions: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.

AB - Background: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers. Patients and methods: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008 to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with ≥10% nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-square test. Results: The expression rate of AR was 72.9% higher than those of estrogen receptors (ER) and progesterone receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer. However, AR expression was observed in 35% of triple-negative cancers. Metaplastic, medullary and mucinous types of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human epidermal growth factor receptor type 2 (HER-2) overexpression. Conclusions: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.

UR - http://www.scopus.com/inward/record.url?scp=77649188673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649188673&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp510

DO - 10.1093/annonc/mdp510

M3 - Article

C2 - 19887463

AN - SCOPUS:77649188673

VL - 21

SP - 488

EP - 492

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

M1 - mdp510

ER -

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH et al. Expression of androgen receptors in primary breast cancer. Annals of Oncology. 2009 Nov 3;21(3):488-492. mdp510. https://doi.org/10.1093/annonc/mdp510